Immunovant Inc [NASDAQ: IMVT] gained 8.03% or 1.22 points to close at $16.42 with a heavy trading volume of 3711950 shares.
The daily chart for IMVT points out that the company has recorded -42.41% loss over the past six months.
If we look at the average trading volume of 1.53M shares, IMVT reached to a volume of 3711950 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Immunovant Inc [IMVT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMVT shares is $45.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMVT stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Immunovant Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on March 03, 2025. The new note on the price target was released on January 03, 2025, representing the official price target for Immunovant Inc stock. Previously, the target price had yet another raise to $36, while Raymond James analysts kept a Outperform rating on IMVT stock. On October 09, 2024, analysts increased their price target for IMVT shares from 47 to 53.
The Average True Range (ATR) for Immunovant Inc is set at 1.31 The Price to Book ratio for the last quarter was 6.85, with the Price to Cash per share for the same quarter was set at 2.21.
Trading performance analysis for IMVT stock
Immunovant Inc [IMVT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.22. With this latest performance, IMVT shares dropped by -11.20% in over the last four-week period, additionally sinking by -42.41% over the last 6 months – not to mention a drop of -48.05% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMVT stock in for the last two-week period is set at 37.28, with the RSI for the last a single of trading hit 36.23, and the three-weeks RSI is set at 38.01 for Immunovant Inc [IMVT]. The present Moving Average for the last 50 days of trading for this stock 19.98, while it was recorded at 17.17 for the last single week of trading, and 26.28 for the last 200 days.
Immunovant Inc [IMVT]: A deeper dive into fundamental analysis
Immunovant Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.04 and a Current Ratio set at 6.04.
Immunovant Inc [IMVT]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMVT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Immunovant Inc go to -21.29%.
An analysis of Institutional ownership at Immunovant Inc [IMVT]
There are presently around $49.64%, or 118.41%% of IMVT stock, in the hands of institutional investors. The top three institutional holders of IMVT stocks are: FMR LLC with ownership of 10.48 million shares, which is approximately 7.1765%. VANGUARD GROUP INC, holding 6.51 million shares of the stock with an approximate value of $$171.86 million in IMVT stocks shares; and VANGUARD GROUP INC, currently with $$129.79 million in IMVT stock with ownership which is approximately 3.3652%.
